Lupus and Allied Diseases Association, Inc.

(a) to coordinate and support research and education in the field of lupus and allied diseases with the goal of establishing more effective treatments that are accessible to those suffering from lupus and allied diseases.
(b) to promote the exchange of knowledge about lupus and allied diseases concerning the symptomology, diagnostic methods, treatments, prevention, pathogenesis and cure.
(c) to collaborate with various health organizations such as patient advocacy organizations, professional societies, government entities, and other interested stakeholders in the promotion of lupus and allied diseases program initiatives.
(d) to support biomedical research programs for lupus and allied diseases.
(e) to raise, disburse and administer funds in order to accomplish the aforementioned purposes.

The Lupus and Allied Diseases Association, Inc., believes it is critical for all healthcare stakeholders to collaborate on advocacy and research initiatives. We are very active on both the state and national level regarding health care reform and access issues that impact those affected by lupus including: the biosimilars regulatory process, protecting entitlement programs, providing stronger patient protections, promoting patient-centric research. Our programs are designed to empower individuals to actively participate in their own health care and to also become engaged in the public policy process and across the research continuum in order to influence positive change and enhance their quality of life. Lupus and Allied Diseases Association, Inc. provides Public Education, Advocacy and Awareness programs, collaborates with other interested partners to serve the needs of the lupus and unmet disease communities, and provides representation regarding important lupus-related issues at local and national advocacy events. We also provide patient and care partner experts to participate in research, policy, regulatory and advocacy initiatives to bring our unique perspective to the dialogue.

Lupus and Allied Diseases Association, Inc. addresses access to care issues as they arise, often taking the lead to organize grassroots efforts within the state or nation. We are a prime advocacy group in NYS and have helped to coalesce over 75 patient and professional groups to unite on these important matters. We have also supported access issues in various states and have led and collaborated on national initiatives. We submitted comments on the 21st Century Cures and Senate Healthier Americans Initiative and led the effort for the lupus community to collaborate on the FDA Patient-Focused Drug Development Initiative and an ICER Lupus Drug Review. We remain committed to ensuring the Biosimilars regulatory pathway recognizes the complexities of autoimmune patients and products are safe, efficacious and have distinguishable non-proprietary names.

We have supported $1,848,324.00 since 1990 in lupus research funding.
We have helped to pass legislation that increases lupus and other disease research funding.
We have helped to pass legislation that improves patient access to medical care and critical treatments both federally and in various states.
We have helped to increase lupus awareness through the CDC Public Health Agenda and the Annual NYS Lupus Awareness Event and World Lupus Day Initiative.
We co-led an Externally-led Lupus Patient-Focused Drug Development (PFDD) Initiative.
Advancing research to identify better diagnostic tools, discover more effective treatments with less toxicity and ultimately, cures to improve patient quality of life.